{"created":"2023-06-19T07:25:22.608699+00:00","id":13144,"links":{},"metadata":{"_buckets":{"deposit":"325d6c2d-d36f-42e0-9dc7-a052c3d6a32e"},"_deposit":{"created_by":39,"id":"13144","owners":[39],"pid":{"revision_id":0,"type":"depid","value":"13144"},"status":"published"},"_oai":{"id":"oai:gifu-pu.repo.nii.ac.jp:00013144","sets":["212:361:364"]},"author_link":["18617"],"item_3_biblio_info_3":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2015-08","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"8","bibliographicPageEnd":"1660","bibliographicPageStart":"1652","bibliographicVolumeNumber":"37","bibliographic_titles":[{},{"bibliographic_title":"Clinical therapeutics","bibliographic_titleLang":"en"}]}]},"item_3_text_4":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_text_value":"10.1016/j.clinthera.2015.02.024"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Alzheimer Disease","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Clinical Trials, Phase III as Topic","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Drug Approval","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Humans","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Japan","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Neuroprotective Agents","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"United States","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"United States Food and Drug Administration","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Development of Novel Pharmaceutical Agents for Alzheimer's Disease: The Impact of Regulatory Initiatives in Japan and the United States.","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Development of Novel Pharmaceutical Agents for Alzheimer's Disease: The Impact of Regulatory Initiatives in Japan and the United States.","subitem_title_language":"en"}]},"item_type_id":"3","owner":"39","path":["364"],"pubdate":{"attribute_name":"公開日","attribute_value":"2018-06-14"},"publish_date":"2018-06-14","publish_status":"0","recid":"13144","relation_version_is_last":true,"title":["Development of Novel Pharmaceutical Agents for Alzheimer's Disease: The Impact of Regulatory Initiatives in Japan and the United States."],"weko_creator_id":"39","weko_shared_id":-1},"updated":"2023-06-19T08:58:59.122638+00:00"}